Moderna (MRNA) IPO Opens 4% Lower

December 7, 2018 11:46 AM UTC

Today's IPO for Moderna, Inc. (NASDAQ: MRNA) opened for trading at $22 after pricing 26,275,993 shares of common stock at a public offering price of $23.00 per share.

Moderna has granted the underwriters a 30-day option to purchase up to an additional 3,941,398 shares of Moderna’s common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. BofA Merrill Lynch, Barclays Capital Inc. and Piper Jaffray & Co. are acting as book-running managers for the offering. Oddo BHF SCA, Oppenheimer & Co. Inc., Needham & Company, LLC and Chardan are acting as co-managers for the offering.

Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines to direct the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

IPOs

Related Entities

Piper Jaffray, JPMorgan, Goldman Sachs, Morgan Stanley, Needham & Company, Barclays, Chardan Capital Markets, IPO